Diaceutics PLC(DIUXF)
USD --+0.00%
Reward64Moderate
Risk54Moderate
📊75%Data
Thin -4% profit margin · Revenue growing 18% YoY
DIUXF
+0.0 · +0.00%
USD · PINK
Diaceutics PLC | Healthcare
Profitless Growth
Market Cap:195.54M
ℹ️
Reward Rating
64
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
54
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on DIUXF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Diaceutics PLC?

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.

DIUXF · Verdict

Solid reward · elevated risk

DIUXF's standout is growth; cash flow and profitability weigh on the picture.

Based on 88% data coverage

DIUXF · Verdict

What’s working & what to watch

Strengths 1

  • Growth96/100

    Revenue +32.1% CAGR

Watchouts 3

  • Cash flow27/100

    -12% free-cash-flow margin

  • Profitability32/100

    -5% net margin · -4% ROE

  • Valuation45/100

    P/E 142.9×

Model-based scoring. For information only — not financial advice.

What is Diaceutics PLC?

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 195.54M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (64)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap195.54M
P/E RatioN/A
Dividend YieldN/A
52 Week High1.67
52 Week Low1.3672
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding85M
No. of Employees213
IndustryHealth Information Services
ExchangePINK
Beta1.077
CurrencyUSD · Reports in GBP